Buxbaum, J.D., Oishi, M., Chen, H.I., Pinkas-Kramarski, R., Jaffe, E.A., Gandy, S.E. and Greengard, P. (1992) Cholinergic Agonists and Interleukin 1 Regulate Processing and Secretion of the Alzheimer Beta/A4 Amyloid Protein Precursor. Proceedings of the National Academy of Sciences of the United States of America, 89, 10075-10078. http://dx.doi.org/10.1073/pnas.89.21.10075

has been cited by the following article:

• TITLE: Therapeutic Effects of Curcumin on Alzheimer’s Disease

  AUTHORS: Edward C. Yao, Lei Xue

  KEYWORDS: Alzheimer’s Disease, Curcumin, Beta-Amyloid

  JOURNAL NAME: Advances in Alzheimer's Disease, Vol.3 No.4, November 28, 2014

  ABSTRACT: As the number of patients with Alzheimer’s disease (AD) continues to rise throughout the twenty- first century, scientists are increasingly looking for remedies, although the cause and pathology of the disease remain uncertain. Among treatments for AD, there is a renewed interest in curcumin as a potential medication. Studies of the substance have found a large amount of consumption associated benefits, including anti-inflammatory and antioxidant effects. Its wide healing properties make it increasingly interesting to scientists, with potential uses in the treatment of cancers, arthritis, various cardiovascular diseases, and neurodegenerative diseases. More recently, curcumin has been shown to have multipotent effects against various symptoms of AD. Among other things, curcumin has been able to ameliorate toxicity of beta-amyloid species, a key part of AD nuerodegeneration, in vivo and in vitro, and has been able to inhibit multiple parts along suspected AD pathology. The goal of this review is to summarize the research done on curcumin with respect to its applicability as a treatment for AD and AD related pathology.